Synthetic T3 (3,5,3'-triiodothyronine), Pfizer 1956 FDA-approved hypothyroidism Rx (Cytomel). Cutting-cycle off-label thermogenic +10-30% REE via direct mitochondrial β-oxidation + Na/K-ATPase upregulation; WADA in-competition banned for non-Rx athletes.
The links above are labelled third-party affiliate links. MolekulaX does not sell and does not verify product quality.

WHAT IS LIOTHYRONINE (T3, CYTOMEL)?
Liothyronine (Cytomel) is the synthetic form of endogenous T3 (3,5,3'-triiodothyronine), the pharmacologically active form of thyroid hormone. With FDA approval since 1956 by Pfizer, it is primarily indicated for hypothyroidism where T4 monotherapy fails to produce full remission of cognitive symptoms (Bunevicius 1999 NEJM PMID 9989958 is the classic T3 add-on trial). 70 years of clinical literature plus documented bodybuilding off-label use since the 1980s (Hochberg 1989). T3 acts as a nuclear TR-α and TR-β receptor agonist, triggering direct gene-transcription activation that raises tissue metabolic rate by 10-30% through the nuclear-receptor cascade. The direct mechanism includes mitochondrial β-oxidation upregulation plus Na/K-ATPase density elevation in skeletal muscle, raising resting energy expenditure (REE). In AAS cutting context the T3 cycle (25-75 μg/day, 12.5 μg titration step) is used to balance muscle retention with fat-burning; however, hypothyroid shutdown risk is high (endogenous TSH suppression is dose-dependent, with >100 μg/day for 12+ weeks chronic carrying potential secondary hypothyroidism risk). The WADA list places T3 under S4.5 thyroid hormone modulator, in-competition banned for non-Rx athletes (NADA Switzerland 2023, USADA 2024 update). T4 vs T3: T4 has slower on/off plus a 7-day half-life enabling slow titration; T3 has a 24-hour half-life and fast action but sudden endogenous TSH suppression.
Mechanism of action
Nuclear TR-α + TR-β receptor agonist, gene-transcription activation, +10-30% REE
Dosing
Clinical 25-50 μg/day; off-label cutting-cycle 25-75 μg/day, titration 12.5 μg/step
Half-life
~24 hours (steady-state within 7 days)
Onset
Metabolic-rate increase 24-48 hours, fat-loss effect 1-2 weeks
Legal status
FDA + EMA Rx (hypothyroidism), registered in HU + PL. WADA: S4.5 in-competition banned for non-Rx athletes.
Data console
Safety
Side effects · 7
Contraindications · 7
Related Performance Compounds
Studies
Bunevicius R, Jakuboniene N, Jurkevicius R, Bunevicius A, Lasas L, Prange AJ Jr
Maraka S, Owen RR, Singh Ospina NM
Razvi S, Jabbar A, Pingitore A, Danzi S, Biondi B, Klein I, Peeters R, Zaman A, Iervasi G
Chen S, Wohlford GF, Vecchie' A
Persani L, dell'Acqua M, Ioakim S, Bonomi M
Telegram
Reach out to an advisor on Telegram. Performance compounds are presented with a harm-reduction approach, based on peer-reviewed evidence.
The information here is for educational and scientific purposes only. Performance-enhancing compounds (AAS, prohormones, stimulants, doping agents) are illegal without prescription in Hungary and most of the EU, and carry serious health and legal risks. WADA bans them in competitive sport. This is NOT a usage guide, and we do not encourage any illegal use. If you do use them, medical supervision and regular bloodwork are ESSENTIAL. Severe endocrine, cardiovascular, hepatic and psychiatric side effects are possible.